Evidence map›Paper›PMID 34353305›Full record

ArticleBMC cancer2021

Impact of lenvatinib on renal function: long-term analysis of differentiated thyroid cancer patients.

Chie Masaki, Kiminori Sugino, Sakiko Kobayashi, Yoshie Hosoi, Reiko Ono, Haruhiko Yamazaki, Junko Akaishi, Kiyomi Y Hames, Chisato Tomoda, Akifumi Suzuki and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Chie MasakiDepartment of Surgery, Ito Hospital, Tokyo, 150-8308, Japan. c-masaki@ito-hospital.jp.
Kiminori SuginoDepartment of Surgery, Ito Hospital, Tokyo, 150-8308, Japan.
Sakiko KobayashiDepartment of Internal Medicine, Keio University School of Medicine, Tokyo, 160-8582, Japan.
Yoshie HosoiDepartment of Surgery, Ito Hospital, Tokyo, 150-8308, Japan.
Reiko OnoDepartment of Surgery, Ito Hospital, Tokyo, 150-8308, Japan.
Haruhiko YamazakiDepartment of Surgery, Ito Hospital, Tokyo, 150-8308, Japan.
Junko AkaishiDepartment of Surgery, Ito Hospital, Tokyo, 150-8308, Japan.
Kiyomi Y HamesDepartment of Surgery, Ito Hospital, Tokyo, 150-8308, Japan.
Chisato TomodaDepartment of Surgery, Ito Hospital, Tokyo, 150-8308, Japan.
Akifumi SuzukiDepartment of Surgery, Ito Hospital, Tokyo, 150-8308, Japan.
Kenichi MatsuzuDepartment of Surgery, Ito Hospital, Tokyo, 150-8308, Japan.
Keiko OhkuwaDepartment of Surgery, Ito Hospital, Tokyo, 150-8308, Japan.
Wataru KitagawaDepartment of Surgery, Ito Hospital, Tokyo, 150-8308, Japan.
Mitsuji NagahamaDepartment of Surgery, Ito Hospital, Tokyo, 150-8308, Japan.
Koichi ItoDepartment of Surgery, Ito Hospital, Tokyo, 150-8308, Japan.
Ito Hospital · JPKeio University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBecause lenvatinib is well known to induce proteinuria by blocking the vascular endothelial growth factor (VEGF) pathway, renal function is a concern with long-term administration of lenvatinib. The long-term effects of lenvatinib on renal function in patients with advanced differentiated thyroid carcinoma (DTC) were analyzed.

methodThis study involved 40 DTC patients who continued lenvatinib therapy for ≥6 months. Estimated glomerular filtration rate (eGFR) was calculated as an indicator of renal function. The temporal course of eGFR, effects of baseline eGFR on eGFR changes, and factors affecting renal impairment were investigated.

resultsThe overall cohort showed sustainable decreases in eGFR, with decreased values of 11.4, 18.3, and 21.0 mL/min/1.73 m

conclusionLenvatinib can induce declines in eGFR, particularly with treatment duration > 2 years, regardless of baseline eGFR. Proteinuria is a risk factor for declines in eGFR. Patients who start lenvatinib with better renal function show a renal reserve capacity, prolonging clinical outcomes. Decision-making protocols must balance the benefits of lenvatinib continuation with acceptable risks of harm.

Indexed as

AdultAgedAntineoplastic AgentsFemaleGlomerular Filtration RateHumansKidneyKidney DiseasesKidney Function TestsMaleMiddle AgedPhenylurea CompoundsProtein Kinase InhibitorsQuinolinesThyroid NeoplasmsTime FactorsAntineoplastic AgentslenvatinibPhenylurea CompoundsProtein Kinase InhibitorsQuinolinesVascular Endothelial Growth Factor AAdvanced thyroid carcinomaeGFRLenvatinibProteinuriaRenal function

Identifiers

PMID34353305
PMCPMC8340367
OpenAlexW3120831559

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.